%0 Journal Article
%T First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
%A Alvydas Mikulskis
%A Heather Stella
%A Jeff Sevigny
%A John O'Gorman
%A Kate Leitermann
%A Leslie Williams
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2016
%R 10.1016/j.trci.2016.06.002
%X Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta, is being investigated as a disease-modifying treatment for Alzheimer's disease (AD)
%K Alzheimer's disease
%K Monoclonal antibody
%K Clinical trial
%K Pharmacokinetics
%K Adverse events
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651340/